Traws Pharma ratutrelvir shows fewer adverse events and no viral rebound in interim Phase 2 COVID-19 data vs PAXLOVID

Traws Pharma, Inc.

Interim analysis of 37 patients: 25 on ratutrelvir 600 mg once daily 10 days, 12 on PAXLOVID 5-day regimen.
No viral rebound observed in ratutrelvir arm; 1 rebound (8.3%) in PAXLOVID arm.
24% of ratutrelvir cohort were PAXLOVID-ineligible; symptom improvement consistent with broader group.
Adverse events lower: 7.6% mild dyspepsia on ratutrelvir vs 30% dysgeusia/dizziness/dyspepsia on PAXLOVID.
Final data expected January 2026; enrollment >50% of planned 90-patient study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.